Challenging the dogma of homogeneity in gestational diabetes

MRC · United Kingdom government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

October 31, 2026
Response Due
Active
Status

Opportunity Overview

The number of women who develop diabetes in pregnancy (gestational diabetes) is increasing. Women of South Asian ethnicity are particularly affected. This common disorder which is associated with high blood glucose increases the risk of several pregnancy complications, most of which relate to the baby growing too large. These risks include difficulties during labour and stillbirth. Also, there is increased chance of the mother developing lifelong type 2 diabetes.
At present, all women who develop gestational diabetes receive the same treatment approach. This is because doctors view gestational diabetes as one condition. Research in non-pregnant people with type 2 diabetes is beginning to show that there may be many different types of diabetes. Similarly, evidence is emerging which suggests that doctors should think of gestational diabetes as a group of different disorders, all leading to high blood glucose. This study aims to unpick the different types of gestational diabetes and we shall see if these are the same in South Asian and White European women. If successful we shall then be able to treat each woman according to their type of diabetes, and work towards preventing type 2 diabetes after pregnancy.
This work will begin by defining more accurately two proposed pathways to GDM:-
1. GDM arising from problems of glucose uptake in the liver, fat and skeletal muscle. In one subtype of GDM, it is proposed that the normal transfer of glucose into tissues is reduced because the tissues don't respond to insulin, leading to glucose not being taken up from the blood, resulting in raised blood levels.
2. GDM arising from inefficient secretion of insulin from the beta-cells of the pancreas. In normal pregnancy, all women become a little insulin resistant, but cells in the pancreas (beta-cells) respond by producing more insulin. In this, second type of GDM it is proposed that the pancreatic insulin response is insufficient, and glucose rises in the blood.
We will recruit...

This is one of 1,831 active United Kingdom Research Development opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyMRC
CountryUnited Kingdom
CategoryResearch Development
PublishedNovember 01, 2022
Procurement stageActive solicitation
Response dueOctober 31, 2026
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 12, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Related Opportunities in United Kingdom

Rotation year
Title of project: Evaluation of the quantitative accuracy and radiation dosimetry of an advanced pre-clinical multipinhole SPECT/CT theranostic imag
Discerning MCT1s role in chromatin remodelling and metabolomics changes in cancer progression
Leveraging real world data to characterise the long term impact of COVID-19
Bacterial antibiotic resistance: structure, mechanism and inhibition of ABC transporters responsible for drug efflux and cell wall biogenesis.
Characterising the role of TEX12 in centrosome and cilia development
Allogeneic Chondroprogenitor Therapy (Phase II) (ACT2)
Iron and immunity

See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Research Development intelligence report in your inbox

A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.